Drugs / High-Dose Trivalent Inactivated Influenza Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01525004 | Sep 2011 → Jun 2012 | disease related to solid organ transplantation | Vanderbilt University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01258595 | Nov 2010 → Mar 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01215734 Comparator | Oct 2010 → Apr 2012 | disease related to hematopoietic stem cell transplant | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02553343 Comparator | Sep 2015 → Apr 2016 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-dose trivalent inactivated influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02553343 ↗ |
| Known as | HD-TIV | “High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)” NCT01215734 ↗ |
| Modality | Vaccine | “High-Dose Trivalent Inactivated Influenza Vaccine” NCT01215734 ↗ |
| Route | Intramuscular | “0.5 mL Intramuscular” NCT01258595 ↗ |